Drugs Made In America Acquisition II Corp. Ordinary Shares

DMII | NASDAQ

$10.20

$0.00 (0.00%)

At close: Oct 30, 2026, 3:59 PM ET

$10.19

-$0.01 (-0.10%)

After-hours: Oct 30, 2026, 4:02 PM ET

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q3 2024 Sep 30, 2024
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-112.23K	-132.03K	-1.05M	-155.51K	-38.07K	-59.33K	-41.68K
Interest Income	4.51M	4.44M	-109.36K	109.36K	n/a	n/a	n/a
Pretax Income	4.4M	4.34M	4.33M	-46.16K	-38.07K	-59.33K	-41.68K
Net Income	4.4M	4.34M	4.33M	-46.16K	-38.07K	-59.33K	-41.68K
Selling & General & Admin	112.23K	132.03K	235.47K	155.51K	38.07K	59.33K	41.68K
Research & Development	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Expenses	n/a	n/a	812.11K	n/a	n/a	n/a	n/a
Operating Expenses	112.23K	132.03K	1.05M	155.51K	38.07K	59.33K	41.68K
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	112.23K	132.03K	1.05M	155.51K	38.07K	59.33K	41.68K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	50M	50M	13.29M	2.72M	33.21M	63.7M	63.7M
Shares Outstanding (Diluted)	50M	50M	13.29M	2.72M	33.21M	63.7M	63.7M
EPS (Basic)	0.07	0.07	0.18	-0.02	n/a	0	n/a
EPS (Diluted)	0.07	0.07	0.17	-0.02	n/a	0	n/a
EBITDA	-112.23K	-132.03K	-1.05M	-155.51K	-38.07K	-59.33K	-41.68K
EBIT	-112.23K	-132.03K	-1.05M	-155.51K	-38.07K	-59.33K	-41.68K
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a